Gary Schuster, MD
Internal Medicine · Bellevue, WANPI 1053500223
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 799 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 12.4% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 799 payments — averaging $19.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Amgen$2K
- Pfizer$1K
- AstraZeneca$1K
- Biohaven Pharmaceuticals, Inc.$581
- Novo Nordisk$572
- plus $8K from 54 others
What the payments were for
- Food & beverage$15,23298%
- Education$3022%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$15,533 in reported general payments places this provider in the 95th percentile of 2,038 internal medicine providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 140 | $126,735 |
| MounjaroTirzepatide | 62 | $72,633 |
| OzempicSemaglutide | 29 | $36,175 |
| JardianceEmpagliflozin | 25 | $34,537 |
| EliquisApixaban | 25 | $30,933 |
| RybelsusSemaglutide | 12 | $24,448 |
| ProliaDenosumab | 14 | $24,029 |
| NexlizetBempedoic Acid/Ezetimibe | 11 | $13,132 |
| Praluent PenAlirocumab | 13 | $10,735 |
| TrintellixVortioxetine Hydrobromide | 15 | $10,097 |
| Ezetimibe | 203 | $7,019 |
| EdarbyclorAzilsartan Med/Chlorthalidone | 15 | $6,591 |
| Rosuvastatin Calcium | 344 | $4,905 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $4,659 |
| PremarinEstrogens, Conjugated | 13 | $3,783 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $518 | $72,63362 claims |
| Novo NordiskOzempic, Rybelsus | $572 | $60,62341 claims |
| PfizerEliquis, Premarin, Paxlovid | $1,433 | $37,57483 claims |
| Boehringer IngelheimJardiance | $242 | $34,53725 claims |
| AmgenProlia | $1,668 | $24,02914 claims |
| Esperion Therapeutics, Inc.Nexlizet | $314 | $13,13211 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $375 | $10,09715 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor | $134 | $6,59115 claims |
| AstraZenecaSymbicort | $1,229 | $4,65911 claims |
| AbbVieSynthroid | $1,922 | $2,82138 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,038 internal medicine providers in Washington.
Other internal medicine in Bellevue
- Lawrence LoebBellevue$784K
- Tatyana KutsyBellevue$13K
- Peter ShalitSeattle$1M
- Shawna PurcellOlympia$294K
- Scott RamseySeattle$230K
- Michael CairnsSeattle$144K
- Peiqing QianSeattle$117K
- Alan KellySpokane Valley$96K
- Emily EgdaminWenatchee$81K
- Royce MorrisonTacoma$72K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.